OUR PEOPLE
A trusted team. A proven track record.
Elion Therapeutics leadership possesses more than 200 years of collective academic, chemistry, nonclinical, clinical, manufacturing, and regulatory experience in the development of almost every antifungal agent available today. We are excited to carry this legacy forward with EL219.
Leadership team
Shawn Flanagan
Senior Vice President, Clinical Pharmacology & Translational Development
Board of directors
Kieren Marr
Elion Therapeutics
Martin Heidecker
AMR Action Fund
Jonathan Leff
Deerfield Management Company
Eddie Yang
Deerfield Management Company
Paul Truex
Independent
Investors
AMR Action Fund
The AMR Action Fund is a mission-driven venture capital fund investing in antibiotics, antifungals, and other antimicrobial technologies. The Fund plans to invest approximately US$1 billion into clinical-stage biotech companies to help bring two to four new antibiotics to market by 2030.
Deerfield Management Company
Launched in 1994, Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative, and inclusive ways. For more information, visit deerfield.com.
Illinois Ventures
Launched in 2000, Illinois Ventures manages return-focused venture funds and is an evergreen fund for seed-stage start-ups from the University of Illinois system.
The namesake of Elion Therapeutics is the Nobel Prize winner Gertrude B. Elion (1918-1999), a pioneer in rational drug design. Her scientific dedication and legacy provide enduring inspiration to this day.